ProNAi has  developed its first drug candidate, PNT2258, to Phase 1 clinical development The company’s lead product candidate, PNT2258, has demonstrated in vivo efficacy in human tumor xenograft models.  ProNAi has an open IND and plans to commence a Phase I clinical trial with PNT2258 post B Round financing.
Since ProNAi was established in May 2004, the company has made rapid and substantial progress in advancing its first product candidate. The company has:

• Advanced PNT2258, its lead drug product candidate, from discovery to IND-enabling studies in 24 months. Preclinical studies have demonstrated striking synergistic activity with Rituxan® (rituxumab) in a Rituxan-resistant xenograft model of non-Hodgkin’s Lymphoma (NHL) and activity with Taxotere® (docetaxel) in models of hormone resistant prostate cancer and melanoma.
  
• Developed a proprietary product formulation and an efficient GMP manufacturing process for PNT2258 to support its entry into clinical trials.
  
• Identified follow-on products against frequently aberrant oncogenes. The table below highlights ProNAi’s current pipeline of products: